Division of AIDS Safety Office EXPEDITED ADVERSE EVENT (EAE) Form

Similar documents
GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

SAE håndtering i protokol CC MM-001

Tocilizumab Guided Questionnaire Myocardial Infarction/Acute Coronary Syndrome

Serious Adverse Event (SAE) Form Clinical Trials

Tocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events

Serious Adverse Event (SAE) Form Clinical Trials

Tocilizumab/Roactemra Guided Questionnaire Anaphylaxis/Serious hypersensitivity reaction

Serious Adverse Event Report Form (CTIMP)

DAIDS Adverse Experience Reporting System (DAERS) Site User Instructional Guide for EAE Reporting

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

Adverse Experience Reporting

ARKANSAS STATE BOARD OF ATHLETIC TRAINING 9 SHACKLEFORD PLAZA, SUITE 3 LITTLE ROCK, AR 72211

If the HPTN 082 protocol is amended in the future, this Letter of Amendment will be incorporated into the next version.

How to Apply: The Application Process

Cover Sheet for Example Documentation

Personal Information. Full Name: Address: Primary Phone: Yes No Provider Yes No. Alternate Phone: Yes No Provider Yes No

ASSIGNED TREATMENT ARM

These materials are Copyright NCHAM (National Center for Hearing Assessment and Management). All rights reserved. They may be reproduced

DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]

Fertility Specialty Care

68 Ga-DOTAXXX Template Case Report Forms (CRFs) Table of Contents

CAMP SIGN DARS-DRS. Office for Deaf and Hard of Hearing Services North Lamar Blvd., Ste. 3427; Austin, Texas 78751

adsm TB Version July 25 th, 2016

Demographics. 2. What was your sex at birth? If female, participant is ineligible. End of form.

SUSPECT ADVERSE REACTION REPORT

FormsNet Adverse Event Form

Chickenpox Death. West Virginia Electronic Disease Surveillance System

National Deaf-Blind Equipment Distribution Program Application

LUCAS CHIROPRACTIC 903 Howard St. Walla Walla WA PATIENT INTAKE - update

SCNIR 1107 NE 45 th St, Suite #345 Seattle, WA REGISTRATION FORM. Reviewer s Signature: PHYSICIAN CONTACT INFORMATION

Tuberculosis in Chicago 2006

IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No

SUSPECT ADVERSE REACTION REPORT

RITAZAREM. CRF Completion Guidelines

select class BEST VALUE! $85 $90 $55 $60 $40 $45

STATE OF ARKANSAS OFFICE OF STATE PROCUREMENT 1509 West 7th Street, Room 300 Little Rock, Arkansas BID RESPONSE PACKET

SUSPECT ADVERSE REACTION REPORT

Patient Information. First Name Middle Last Preferred Name. Street Address City State Postal Code

CASE HISTORY (ADULT) Date form completed:

Understanding Adverse Events

THURGOOD MARSHALL ACADEMY PCHS ATHLETIC INFORMATION PACKET SY

GUIDELINE ON FILLING THE CIOMS FORM

COLLEGIATE RECOVERY PROGRAM APPLICATION

November 9, Clarification Memo 1 Version 3.0 HVTN 704/HPTN 085

<<UNIVERSITY X>> Operation Diabetes APhA Academy of Student Pharmacists (APhA ASP) SAMPLE Screening Site Location(s)

Welcome to Medina Family Chiropractic and Acupuncture!

HEALTH HISTORY FORM. Student PID Number Date of Birth Legal Sex Preferred Pronouns Relationship Status (ie. he/him, she/her, they/their)

SUSPECT ADVERSE REACTION REPORT

Safety Manual: DAD Trial

Hepatitis Case Investigation

Health Clearance FAQ s

School Consultation Project Application

Patient Enrollment Sheet

Washington County-Johnson City Health Department Christen Minnick, MPH, Director 219 Princeton Road Johnson City, Tennessee Phone:

Influenza-Associated Pediatric Deaths Case Report Form

Name: Phone #: Address: Cell Phone #: Address: I d like to participate in:

Vision/Lifestyle Questionnaire

Transitional Housing Application

Arkansas Association of the Deaf High School Scholarship Program

PRIMARY INSURANCE. Subscriber Name: Subscriber ID/Policy #: Relationship to Patient: Self Wife Husband Parent Other Assignment of Insurance Benefits

CHEMICAL DEPENDENCY CLINIC

Barbara Varnum, Director 1 (800) (V, TTY) (406) (local) (V, TTY

Action Request Transmittal

NATIONAL CERTIFICATE IN TOBACCO TREATMENT PRACTICE (NCTTP) APPLICATION

Adult Education. If you have any questions, please contact the Student Health Services office at (914) , extension 2243.

Client Intake Form Therapeutic Massage

NEW PATIENT HEALTH HISTORY

Name: Date of Birth: Address: City: State: Zip Code: Phone Number: Cell Phone: Work Number: Race: Primary Language: Secondary Language:

ILI Syndromic Surveillance

SUSPECT ADVERSE REACTION REPORT

Holy Family University, Student Health Services, Directions for Completion of Health Packet

Diphtheria. West Virginia Electronic Disease Surveillance System

Drug Prior Authorization Form Alertec (modafinil)

DENTAL CLINICAL RESIDENCY PROGRAMME

CHRONOLOGICAL RECORD OF MEDICAL CARE Behavioral Medicine Associates, Inc North Virginia Avenue Roswell, NM 88201

Radford University School of Nursing GRADUATE HEALTH RECORD FORM

December 14, Letter of Amendment 1 Version 2.0 HVTN 704/HPTN 085

Providing Highly-Valued Service Through Leadership, Innovation, and Collaboration. July 30, Dear Parents and Community Members:

SUSPECT ADVERSE REACTION REPORT

Nutrition First Because it matters.

Technical Meeting on the Security of Nuclear and other Radioactive Material in Transport

Adverse Event Monitoring and Reporting

Human Immunodeficiency Virus (HIV) Specialty Endorsement. Application. RICB HIV Specialty Endorsement Application June

SUSPECT ADVERSE REACTION REPORT

Tuberculosis in Chicago 2007

Medicare & Dual Options. 1. Every page of the EMR document must include: a. Member Name b. Patient Identifiers (i.e. Date of Birth) c.

PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006

Dr. Charles E. Copeland, DC Highland Chiropractic

WELCOME TO AGEWELL MEDICAL ASSOCIATES

SUSPECT ADVERSE REACTION REPORT

Pertussis. West Virginia Electronic Disease Surveillance System

SUSPECT ADVERSE REACTION REPORT

Chapter 8: Safety, Adverse Events and Endpoints

8.0 ADVERSE EVENT HANDLING

Survey of Dentists in Delaware

FIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Name of person previously tested and relationship:

SUSPECT ADVERSE REACTION REPORT

NATIONAL CERTIFICATE IN TOBACCO TREATMENT PRACTICE (NCTTP) TEST EXEMPTION OFFER APPLICATION VALID: OCTOBER 15, APRIL 15, 2018

ONCOLOGY OUTCOMES REPORT

Transcription:

To: DAIDS SAFETY OFFICE Division of AIDS Safety Office EXPEDITED ADVERSE EVENT (EAE) Form Sent by: Please type or print in English Fax: 1-800-275-7619 (USA) or + 1-301-897-1710 (International) Phone: 1-800-537-9979 (USA) or + 1-301-897-1709 (International) Email: RCCSafetyOffice@Tech-Res.com Phone: Fax: E-mail: Date Sent: No. of Pages: (Including this cover sheet) Patient/Volunteer ID Number: REPORTER AND SITE INFORMATION Site Name: Site Number: Site Awareness Date: Reporter Same as Sender? YES NO If YES, do not repeat contact information provided above. Reporter Name: Phone: Email: New Report: Fax: (Send all pages of the completed form.) Follow-up Report: (If Follow-up Report, provide Date of Original Report.) Date of Original Report: Pages: 1 2 3 4 5 6 7 ALL (For Follow-up Reports, submit only updated pages. Check all that apply.) SAFETY OFFICE USE ONLY Received Date Stamp: AE NUMBER: PROTOCOL NUMBER(S): Report Received By: Fax E-mail Express Mail Page 1

Is this a Serious Adverse Event (SAE) as defined in ICH* E6? (* International Conference on Harmonisation ) YES NO Results in death Is a congenital anomaly/birth defect Results in persistent or significant disability/incapacity Is life-threatening Requires inpatient hospitalization or prolongation of existing hospitalization 1. PROTOCOL INFORMATION Protocol Number: Protocol Number: N/A Protocol Number: N/A Network Affiliation (check one): AACTG AIEDRP CIPRA CPCRA Network Affiliation (check one): AACTG AIEDRP CIPRA CPCRA Network Affiliation (check one): AACTG AIEDRP CIPRA CPCRA ESPRIT HPTN HVTN IRP ESPRIT HPTN HVTN IRP ESPRIT HPTN HVTN IRP PACTG SMART Other Network, specify PACTG SMART Other Network, specify PACTG SMART Other Network, specify 2. SUBJECT INFORMATION For each question below, please check the appropriate box. Age: Days* Months* Years Sex at Birth: Male Female Unknown Pregnant: Yes No Unknown Race: Native American or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander Unknown White Other, specify (If Yes) Duration week(s) Height * : cm in Weight: kg lb * Pediatric Studies Only Page 2

3. FOR ALL STUDY AGENTS For therapeutics administered on a cyclic schedule, also complete the Supplemental DAIDS EAE Report Form and check here if attached. A Protocol Number B C D 4. FOR STUDY AGENTS OTHER THAN VACCINES OR THERAPEUTIC VACCINES N/A * C Continued Without Change; O Course Completed or Subject Off Study Agent at AE Onset; D Permanently Discontinued; R Dose or Schedule Reduced; T Temporarily Held; U Unknown Study Agent Agent 1 Agent 2 Agent 3 Agent 4 Agent 5 Generic/INN Name or the Study Agent Name/ Abbreviation as listed in the Protocol. If Combination Agent, use Study Agent name/abbreviation or list individual components. Dose Route Study Agent Agent 1 Agent 2 Agent 3 Agent 4 Agent 5 A Schedule of Administration B Date of First Dose C D E Date of Last Dose Action Taken with Study Agent * Date of Action Taken with Study Agent Distributed by DAIDS Yes No Yes No Yes No Yes No Yes No F If No, specify manufacturer. If unknown, specify distributor. Page 3

5. FOR VACCINES ONLY (INCLUDING THERAPEUTIC VACCINES) List all dates of vaccine administration. N/A * C Continued Without Change; O Course Completed or Subject Off Study Agent at AE Onset; D Permanently Discontinued; R Dose or Schedule Reduced; T Temporarily Held; U Unknown a. / / c. / / e. / / D D M O N Y Y Y Y D D M O N Y Y Y Y D D M O N Y Y Y Y b. / / d. / / f. / / D D M O N Y Y Y Y D D M O N Y Y Y Y D D M O N Y Y Y Y Action Taken with Study Agent * (enter code for the vaccine treatment regimen from codes listed above): Page 4

6. PRIMARY ADVERSE EVENT PRIMARY AE List only one Primary AE. Relationship to Study Agent(s) Listed in Section 3 * Agent 1 Agent 2 Agent 3 Agent 4 Agent 5 Severity Grade of Primary AE Onset Date Status Code ** Status Date * Relationship Code ** Status Code at Most Recent Observation 1 Definitely Related 1 Recovered / Resolved 2 Probably Related 2 Recovering / Resolving 3 Possibly Related 3 Not Recovered / Not Resolved 4 Probably Not Related 4 Recovered / Resolved with Sequelae 5 Not Related 5 Death 6 Pending (temporary assignment for death) 6 Unknown 7. OTHER CLINICALLY SIGNIFICANT EVENTS ASSOCIATED WITH PRIMARY AE Other Clinically Significant Events Associated with Primary AE Severity Grade Onset Date 1. 2. 3. 4. 5. Page 5

8. RELEVANT LABORATORY TESTS List normal or abnormal tests that help explain the Primary AE. List tests below OR attach copy of test results. 1. 2. 3. 4. Collection Test Date Result Units Lab Normal Range Lab Value Previous to this AE Previous Lab Collection Date 9. RELEVANT DIAGNOSTIC TESTS (NON-LAB) List tests below OR attach copy of test results. 1. Test Test Date Results/Comments 2. 3. 4. 10. CONCOMITANT MEDICATIONS List Concomitant Medications being taken at onset of primary AE OR attach copy of concomitant medication(s) list. DO NOT list medications used to treat the AE. Concomitant Medication Approximate Duration of Use 1. 2. 3. 4. 5. 6. 7. Page 6

11. NARRATIVE CASE SUMMARY Include clinical course, therapeutic measures, outcome, relevant past medical history, any other contributing factors, alternative etiologies, and other relevant information. Use additional page(s) as needed. 12. ADDITIONAL INFORMATION Check the box for each type of document attached. Check all that apply. Autopsy Report Diagnostic Imaging Progress Note(s) Pathology Report(s) Discharge Summary Laboratory Report(s) Other, specify CERTIFIER INFORMATION I CERTIFY THAT THE DATA PROVIDED ON THIS FORM ARE ACCURATE AND COMPLETE. Radiology Report(s) Study Physician Signature: Study Physician Name Printed: Date: Page 7

SUPPLEMENTAL DAIDS EXPEDITED ADVERSE EVENT (EAE) FORM Use for therapeutic study agents administered on a cyclic schedule. For multiple study agents on a cyclic schedule, use one page for each study agent. Study Agent Name: 1. If event occurred during a dosing cycle: N/A a. Highest dose in this cycle: b. Dose at time of AE onset: c. Date this cycle started: d. Date previous cycle started: e. Number of previous cycles: 2. If event did not occur during a dosing cycle: N/A a. Highest dose in previous cycle: b. Last dose in previous cycle: c. Date previous cycle started: d. Number of previous cycles: Page